ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire • 11/15/24
Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024Business Wire • 11/12/24
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European PatentBusiness Wire • 11/06/24
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in GermanyBusiness Wire • 10/22/24
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing RequirementsBusiness Wire • 08/28/24
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire • 08/22/24
ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024Business Wire • 08/13/24
ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14Business Wire • 08/07/24
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire • 05/14/24
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024Business Wire • 05/07/24
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsBusiness Wire • 05/02/24
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateBusiness Wire • 03/28/24
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024Business Wire • 03/21/24
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS SystemBusiness Wire • 02/21/24